Gefitinib: phase II and III results in advanced non-small cell lung cancer
- 1 February 2004
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 31, 93-99
- https://doi.org/10.1053/j.seminoncol.2003.12.020
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor TypesJournal of Clinical Oncology, 2002
- Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- ZD1839 (Iressa™): What's in It for the Patient?The Oncologist, 2002
- ZD1839: targeting the epidermal growth factor receptor in cancer therapyExpert Opinion on Investigational Drugs, 2002
- ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- Epidermal growth factor-related peptides and their receptors in human malignanciesPublished by Elsevier ,2000
- Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer TherapyDrugs, 2000
- EGF receptorThe International Journal of Biochemistry & Cell Biology, 1999
- Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrumentPublished by Elsevier ,1995